This led to the identification of already known regulators and/or gene correlations (e.g., hypermethylation of BRCA1 in OV tumor) and to unveil a set of still unknown and potentially interesting biological relationships (e.g., the correlation between ERCC1 and ERCC2, or between CHEK1 and DNMT1 in OV) for their pharmacological and clinical use. This evidence concerns the gene ERCC2 and neoplasm.